|
42 Companies |
|
63 Products |
|
63 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
232 News |
|
| «12345» |
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Trial primary completion date: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 10, 2015
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2016
- lithium carbonate ER / Generic mfg.
Enrollment closed, Trial primary completion date: Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 20, 2015
P1, N=24, Active, not recruiting, Sponsor: Paolo Caimi, MD
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- Trial termination: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 20, 2015
P1, N=13, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015 Active, not recruiting --> Terminated; Inadequate accrual rate
- Trial completion, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 14, 2015
P1, N=3, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; Inadequate accrual rate Active, not recruiting --> Completed
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial suspension: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=19, Suspended, Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed Recruiting --> Suspended
- Ninlaro (ixazomib) / Takeda
Trial suspension: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=16, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial suspension: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2015
P2, N=33, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Trial suspension: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Suspended, Sponsor: Stanford University
Recruiting --> Suspended Recruiting --> Suspended
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2015
P1, N=24, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Suspended Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Jul 21, 2015
P2, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> Dec 2016
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jan 2014 --> Dec 2016 Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2015
P2, N=92, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Active, not recruiting --> Completed
- ||||||| zosuquidar (LY335979) / Kanisa Pharma
Trial completion: Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia (clinicaltrials.gov) - Jun 24, 2015
P3, N=449, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Jun 20, 2015
P2, N=4, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Lack of funding
- Enrollment closed, Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Terminated; Lack of funding Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date, Combination therapy: Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=195, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016
- Enrollment change, Trial primary completion date: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 21, 2015
P1, N=13, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016 N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015
- Biomarker, Enrollment open, Trial primary completion date, IO biomarker: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100
- Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - May 6, 2015
P=N/A, N=15, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100 Trial primary completion date: Apr 2015 --> Apr 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 14, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Mar 2015 --> Sep 2015
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 9, 2015
P2, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Sep 2015 Active, not recruiting --> Completed
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial completion, Enrollment change, Trial primary completion date: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=2, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML (clinicaltrials.gov) - Mar 28, 2015
P3, N=637, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015 Active, not recruiting --> Completed
- Enrollment change, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 19, 2015
P1, N=3, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=34 --> 3
- pravastatin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=19, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=34 --> 3 Active, not recruiting --> Completed | N=50 --> 19
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 19, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed | N=50 --> 19 Trial primary completion date: Mar 2014 --> Mar 2015
- pravastatin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment closed: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- MK-2206 / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 7, 2015
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=43 --> 19 | Trial primary completion date: Oct 2012 --> Oct 2013
- MK-8776 / Merck (MSD)
Enrollment change: Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 6, 2015
P2, N=10, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=43 --> 19 | Trial primary completion date: Oct 2012 --> Oct 2013 N=52 --> 10
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Trial initiation date, Trial primary completion date: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 9, 2014
P1, N=19, Recruiting, Sponsor: Bruno C. Medeiros
N=52 --> 10 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Dec 2014 | Trial primary completion date: Feb 2016 --> Dec 2016
- ||| Synribo (omacetaxine mepesuccinate) / Teva
Enrollment change: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 5, 2014
P2, N=60, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Dec 2014 | Trial primary completion date: Feb 2016 --> Dec 2016 N=37 --> 60
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment change: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 15, 2014
P2, N=167, Completed, Sponsor: National Cancer Institute (NCI)
N=37 --> 60 N=135 --> 167
- Synribo (omacetaxine mepesuccinate) / Teva
Trial primary completion date: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 4, 2014
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
N=135 --> 167 Trial primary completion date: Nov 2016 --> Nov 2018
- MK-8776 / Merck (MSD)
Enrollment closed, Trial primary completion date: Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 28, 2014
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2016 --> Nov 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2015
- Enrollment open: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=15, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2015 Active, not recruiting --> Recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2014
P2, N=111, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Oct 2014
- dilanubicel (NLA101) / Nohla Therap
Trial completion, Enrollment change, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 15, 2014
P1, N=29, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2015 --> Oct 2014 Active, not recruiting --> Completed | N=40 --> 29
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment open: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 30, 2014
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=40 --> 29 Not yet recruiting --> Recruiting
- | thioguanine / Generic mfg., melphalan / Generic mfg.
Trial completion: Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 28, 2014
P1, N=35, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| cladribine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial initiation date: Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 27, 2014
P2, N=120, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Initiation date: Apr 2000 --> Mar 1998
- | cladribine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 23, 2014
P2, N=120, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2000 --> Mar 1998 No longer recruiting --> Completed
- Enrollment closed: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=15, Active, not recruiting, Sponsor: University of Washington
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 28, 2014
P2, N=135, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> May 2014
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 28, 2014
P2, N=135, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> May 2014 Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov) - May 25, 2014
P1/2, N=95, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Trial completion, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2014
P2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Synribo (omacetaxine mepesuccinate) / Teva
Trial initiation date: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2014
P2, N=37, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Initiation date: Apr 2014 --> Jun 2014
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment change: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 5, 2014
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2014 --> Jun 2014 N=46 --> 25
- Ninlaro (ixazomib) / Takeda
Trial initiation date: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 23, 2014
P2, N=16, Recruiting, Sponsor: Bruno C. Medeiros
N=46 --> 25 Initiation date: Dec 2013 --> Mar 2014
- Ninlaro (ixazomib) / Takeda
Enrollment open: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 23, 2014
P2, N=16, Recruiting, Sponsor: Bruno C. Medeiros
Initiation date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting